论文部分内容阅读
人类表皮生长因子受体2基因(HER2)定位于17号染色体,编码一种具有酪氨酸激酶活性的跨膜生长因子受体。研究表明,乳腺癌HER2基因扩增或蛋白过表达与疾病进展和不良预后相关,且是靶向治疗的靶点~([1])。目前指南推荐通过免疫组化技术(IHC)检测HER2蛋白的表达,或通过原位杂交技术(ISH)检测HER2基因~([2,3])。原位杂交技术分为显色原位杂交(CISH)和荧光原位杂交(FISH)~([4])。文献对
The human epidermal growth factor receptor 2 gene (HER2) is located on chromosome 17 and encodes a transmembrane growth factor receptor with tyrosine kinase activity. Studies have shown that HER2 gene amplification or protein overexpression in breast cancer is associated with disease progression and poor prognosis, and is a target of targeted therapy (1). Current guidelines recommend the detection of HER2 protein by immunohistochemistry (IHC) or HER2 gene ~ ([2,3]) by in situ hybridization (ISH). In situ hybridization is divided into chromogenic in situ hybridization (CISH) and fluorescence in situ hybridization (FISH) ~ ([4]). Document right